Skip to content

America’s $5.7 Trillion Healthcare Bill: Progress, Warning—or Both?

Glowing bar graph rising from a hospital building labeled St. Jude's Hospital from 2019 to 2024 with percentage increases

Total U.S. health care spending is estimated to have reached $5.7 trillion in 2025, or about $17,400 per person. That’s an increase of 7.3% from 2024 and marks the third year in a row that healthcare costs have risen by more than 7%. The question we should be asking is not if America is spending too much, but rather if Americans are getting enough health for their spending.

While rising spending may be indicative of better access to healthcare, medical innovation, or treatments that allow people to live longer, it can also signal unnecessarily high prices, administrative waste, and a system that is absorbing more of our economy while failing to produce better results.

What is driving the increase?

This spending is being driven largely by increased use of health care services and products, not just soaring medical inflation.

Spending on hospital care was expected to total about $1.8 trillion in 2025, while spending on physician and clinical services neared $1.2 trillion.

Spending on private health insurance was forecast to grow 8.2%, as was Medicaid spending. Additionally, pent-up demand from the pandemic continued to normalize.

Prescription drugs are another key factor. CMS estimates retail spending on prescription drugs will be the fastest-growing major category of health care spending from 2025 to 2034, rising at an average annual rate of 5.7%.

Much of the focus in the near term has been on pricey cancer drugs and GLP-1 medicines used to treat diabetes and obesity. GLP-1s highlight the dilemma facing health care spending.

On one hand, the drugs are costly, and their usage is growing, which strains employer health plans, Medicare, Medicaid and patients in the near term. But if they reduce cardiovascular events, kidney disease and other complications of obesity, they can create substantial long-term value. Thinking of them as merely a cost ignores half the story. But assuming they’ll eventually pay for themselves is conjecture beyond what we know.

The case for higher spending

There are good reasons behind some of our health spending growth. First, if we are utilizing more healthcare services, that can mean we are providing needed care to more people. Visiting a doctor, filling a prescription or finally having that delayed procedure done all increase national health expenditures—but are not inherently wasteful.

Second, innovation in medicine has value. New medicines and medical devices can help make once-fatal diseases manageable. They can reduce our disabilities and improve our quality of life. The benefits of GLP-1 medications, many cancer treatments, and the new wave of cardiovascular drugs may outweigh their high initial costs by extending benefits beyond health care.

Third, healthcare supports millions of jobs and drives economic activity. Our hospitals, physician offices, drug companies, labs, and home health agencies employ Americans and produce goods and services we need.

There will be a real need for more healthcare services as our population continues to age. And lastly, some money spent on healthcare represents value added by shifting to better ways of delivering care, like home health, earlier diagnosis, and treatments that can prevent more costly complications in the future. Increased spending doesn’t always mean we are failing to control costs. Some of it reflects a society that has chosen to allocate more resources to health care.

The case against the current trajectory

The biggest problem with our current direction is that spending growth outpaces our economy.

CMS estimates healthcare spending will grow 5.4% on average each year from 2025 through 2034, while GDP is expected to grow at 4.1%. National health expenditures are projected to reach nearly $9 trillion in 2034 and make up 20.6% of GDP. That’s up from 18% in 2024.

When healthcare takes a larger share of the economy, it crowds out spending in other areas. It puts more stress on government budgets, employer compensation and households. Rising insurance premiums can slow wage growth, while growing Medicare and Medicaid commitments limit investments in education, infrastructure and other public services.

Patients pay more too through premiums, deductibles, taxes and prescription costs. There’s also little evidence that the additional dollars improve health. Administrative costs are still too high. Prices lack transparency. Care is too fragmented. Too often we incentivize volume instead of value. Drug pricing isn’t much better. Pharmaceutical innovation isn’t something we want to discourage.

Patients benefit when manufacturers have incentives to create life-saving treatments. But drug prices are high and eligible patient populations can be very large, leading to extreme exposures for Medicare, Medicaid and commercial budgets. When insurers restrict access to control costs, patients may go without needed care based on their insurance plan design rather than clinical need.

It’s also important to consider how healthcare dollars are distributed. National spending can go up while rural hospitals go bankrupt, we face clinician shortages, and families skip care because they can’t afford it. Total spending does not indicate if the dollars went to the right patients or were used to buy the right services.

The troubling meaning of “slower growth”

Slowed growth in healthcare spending would still reach 6.3% in 2026 and average just under 5% in 2027 and 2028. Those numbers sound good compared with recent history. But not all of that deceleration will stem from productivity gains or price moderation.

About one-third will result from lower insurance enrollment and reduced healthcare utilization. Enhanced subsidies to buy insurance through Affordable Care Act marketplaces are set to expire at the end of 2025. That change is expected to trim direct-purchase insurance enrollment by 3.7 million in 20 26. Medicaid enrollment will decline by 2.6 million over 2027 and 2028 as new restrictions take effect.

As a result of these changes and others, the Congressional Budget Office projects that the share of Americans with health insurance will fall from 91.8% in 2024 to 90.5% in 2034. The difference matters. Holding down spending by eliminating unnecessary services, negotiating better prices and rooting out administrative inefficiencies is good news for everyone.

Holding down spending because people lose coverage or forego care is not. Eliminating coverage may help federal officials balance their budget, but someone bears the cost of that decision. Patients may owe more out-of-pocket. Employers may pick up additional expenses. Hospitals will provide more uncompensated care. Local governments will face higher budgets for safety-net clinics. Going uninsured doesn’t prevent patients from getting sick. Instead, those patients often seek care later and in more expensive

The pros and cons at a glance

The potential benefits

  • More patients are receiving medical services and prescription treatments.
  • Innovative drugs can improve survival, reduce disability and potentially prevent future complications.
  • Healthcare investment supports employment, research and medical infrastructure.
  • An aging population’s growing need for care is being met, at least in part.

The risks and disadvantages

  • Spending continues to outpace GDP and will place increasing pressure on taxes, wages and public budgets.
  • Higher expenditures do not guarantee better outcomes or more equitable access.
  • GLP-1s and other high-cost therapies create immediate affordability challenges.
  • Administrative waste and fragmented incentives remain deeply embedded.
  • Projected spending moderation partly reflects coverage losses rather than improved efficiency.
  • Medicaid reductions and the loss of enhanced ACA subsidies could leave more people uninsured or underinsured.

The right goal is better value—not simply a smaller bill

America should avoid two simplistic conclusions. One is that all spending is bad. More treatment isn’t an unalloyed curse. Better medicines and longer lives have value.

The other is that all innovation is priceless. Effective care can be overpriced if it threatens affordability or squeezes other priorities. A credible strategy would expand access and demand more value.

That means negotiating lower drug prices where there is little competition; embracing outcomes-based payment; simplifying the administrative bureaucracy; improving primary care and prevention; and rigorously assessing whether high-cost treatments cut total long-term costs or just shift them elsewhere.

The projected growth to 20.6% of GDP is no mere wonk’s concern. It is a choice about wages and taxes; public spending and investment; and who shoulders financial risk if someone gets sick. The $5.7 trillion question is therefore not: how can we spend less, at any cost? It is: how can we stop paying more without reliably improving our health? Until Americans can answer that question, slower growth alone shouldn’t be hailed as “healthcare reform”.

Sources: CMS National Health Expenditure Fact Sheet; CMS 2025–2034 forecast summary; Health Affairs national expenditure projections. Figures for 2025 and later are projections rather than finalized expenditure totals.

Topics:

Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

Leave a Reply

Send this to a friend